nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-219-11-52-61nogr-2600Research ArticleХИРУРГИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯSURGICAL GASTROENTEROLOGYВыбор антигипертезивной терапии при различных стадиях метаболически ассоциированной стеатозной болезни печениChoice of antihyprtensive therapy at varios stages of metabolically associated lever diseasehttps://orcid.org/0000-0001-8736-5851ЛазебникЛ. Б.LasebnikL. B.noemail@neicon.ruЧихиреваЛ. Н.ChikhirevaL. N.chihireva_luda@mail.ruЧихиревО. А.ChikhirevO. A.noemail@neicon.ruЛиЕ. Д.LiE. D.noemail@neicon.ruФедеральное государственное бюджетное образовательное учреждение высшего образования Московский государственный медико-стоматологический университет имени А.И. Евдокимова Министерства здравоохранения Российской ФедерацииРоссияA.I. Yevdokimov Moscow State University of Medicine and DentistryRussian FederationООО «Ревмоцентр»РоссияLLC "Revmocentr"Russian Federation2023260320240115261Copyright © Лазебник Л.Б., Чихирева Л.Н., Чихирев О.А., Ли Е.Д., 20242024Лазебник Л.Б., Чихирева Л.Н., Чихирев О.А., Ли Е.Д.Lasebnik L.B., Chikhireva L.N., Chikhirev O.A., Li E.D.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2600

Метаболически ассоциированная стеатозная болезнь печени (МАСБП) и артериальная гипертензия - два хронических прогрессирующих заболевания, требующие комплексного подхода. В статье рассмотрены принципы назначения гипотензивной и гиполипидемической терапии у пациентов с МАСБП в зависимости от стадии заболевания.

Metabolic dysfunction associated steatatotic liver disease (MASLD) and hypertension are two chronic progressive diseases that require a comprehensive approach. The article discusses approaches to the appointment of hypotensive and hypolipidemic therapy in patients with MASLD, depending on the stage of the disease.

метаболически ассоциированная стеатозная болезнь печениМАСБПнеалкогольная жировая болезнь печениНАЖБПартериальная гипертензиятелмисартанлизиноприламлодипингипотензивная терапияMetabolic dysfunction associated steatatotic liver diseaseMASLDnon-alcoholic fatty liver diseaseNAFLDhypertensiontelmisartanlisinoprilamlodipinehypotensive therapyReferencesRinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature [published online ahead of print, 2023 Jun 24]. Hepatology. 2023;10.1097/HEP.0000000000000520. doi: 10.1097/HEP.0000000000000520.Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature [published online ahead of print, 2023 Jun 24]. Hepatology. 2023;10.1097/HEP.0000000000000520. doi: 10.1097/HEP.0000000000000520.Bisaccia G, Ricci F, Khanji MY, et al. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Curr Probl Cardiol. 2023;48(6):101643. doi: 10.1016/j.cpcardiol.2023.101643Bisaccia G, Ricci F, Khanji MY, et al. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Curr Probl Cardiol. 2023;48(6):101643. doi: 10.1016/j.cpcardiol.2023.101643Younossi Z, Anstee QM, Marietti M, et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.Younossi Z, Anstee QM, Marietti M, et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.Estes C, Razavi H, Loomba R, et al. Modelling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and the United States for the period 2016-2030. J Hepatol 2018; 69: 896-904.Estes C, Razavi H, Loomba R, et al. Modelling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and the United States for the period 2016-2030. J Hepatol 2018; 69: 896-904.Ivashkin V.T., Drapkina O.M., Mayev I.V. et al. Non-alcoholic fatty liver disease prevalence among patients outpatient practice of the Russian Federation: DIREG 2 study results. RJGGK. 2015, 6: 31-41.Ivashkin V.T., Drapkina O.M., Mayev I.V. et al. Non-alcoholic fatty liver disease prevalence among patients outpatient practice of the Russian Federation: DIREG 2 study results. RJGGK. 2015, 6: 31-41.Drapkina O.M., Ivashkin V.T. Epidemiologic features of non-alcoholic fatty liver disease in Russia (Results of open multicenter prospective observational study DIREG L 01903). RJGGK. 2014; 24(4): 32-38.Drapkina O.M., Ivashkin V.T. Epidemiologic features of non-alcoholic fatty liver disease in Russia (Results of open multicenter prospective observational study DIREG L 01903). RJGGK. 2014; 24(4): 32-38.Boytsov S.A., Drapkina O.M., Shlyakhto E.V., Konradi A.O., Balanova Yu.A., Zhernakova Yu.V., Metelskaya V.A., Oshchepkova E.V., Rotar O.P., Shalnova S.A. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. doi: 10.15829/1728-8800-2021-3007.Boytsov S.A., Drapkina O.M., Shlyakhto E.V., Konradi A.O., Balanova Yu.A., Zhernakova Yu.V., Metelskaya V.A., Oshchepkova E.V., Rotar O.P., Shalnova S.A. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. doi: 10.15829/1728-8800-2021-3007.Ma J., Hwang S.-J., Pedley A., Massaro J.M., Hoffmann U., Chung R.T., Benjamin E.J., Levy D., Fox C.S., Long M.T. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J. Hepatol. 2017;66:390-397. doi: 10.1016/j.jhep.2016.09.022.Ma J., Hwang S.-J., Pedley A., Massaro J.M., Hoffmann U., Chung R.T., Benjamin E.J., Levy D., Fox C.S., Long M.T. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J. Hepatol. 2017;66:390-397. doi: 10.1016/j.jhep.2016.09.022.Ryoo J.H., Suh Y.J., Shin H.C., Cho Y.K., Choi J.-M., Park S.K. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J. Gastroenterol. Hepatol. 2014;29:1926-1931. doi: 10.1111/jgh.12643.Ryoo J.H., Suh Y.J., Shin H.C., Cho Y.K., Choi J.-M., Park S.K. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J. Gastroenterol. Hepatol. 2014;29:1926-1931. doi: 10.1111/jgh.12643.Sung K.C., Wild S.H., Byrne C.D. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J. Hepatol. 2014;60:1040-1045. doi: 10.1016/j.jhep.2014.01.009.Sung K.C., Wild S.H., Byrne C.D. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J. Hepatol. 2014;60:1040-1045. doi: 10.1016/j.jhep.2014.01.009.Sorrentino P., Terracciano L., D’Angelo S., Ferbo U., Bracigliano A., Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am. J. Gastroenterol. 2010;105:336-344. doi: 10.1038/ajg.2009.587.Sorrentino P., Terracciano L., D’Angelo S., Ferbo U., Bracigliano A., Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am. J. Gastroenterol. 2010;105:336-344. doi: 10.1038/ajg.2009.587.Zhang T., Zhang C., Zhang Y., Tang F., Li H., Zhang Q., Lin H., Wu S., Liu Y., Xue F. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: A prospective cohort study. Atherosclerosis. 2015;240:144-148. doi: 10.1016/j.atherosclerosis.2015.02.049.Zhang T., Zhang C., Zhang Y., Tang F., Li H., Zhang Q., Lin H., Wu S., Liu Y., Xue F. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: A prospective cohort study. Atherosclerosis. 2015;240:144-148. doi: 10.1016/j.atherosclerosis.2015.02.049.Ng CH, Wong ZY, Chew NWS, et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med. 2022;9:942753. Published 2022 Aug 8. doi: 10.3389/fcvm.2022.942753.Ng CH, Wong ZY, Chew NWS, et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med. 2022;9:942753. Published 2022 Aug 8. doi: 10.3389/fcvm.2022.942753.Russian Cardiological Scientific Society.Russian Scientific Medical Society of Therapists. Clinical recommendations. Arterial hypertension in adults. 2020. (in Russ.)@@ Российское кардиологическое научное общество. Российское научное медицинское общество терапевтов. Клинические рекомендации. Артериальная гипертензия у взрослых. 2020.Russian Cardiological Scientific Society.Russian Scientific Medical Society of Therapists. Clinical recommendations. Arterial hypertension in adults. 2020. (in Russ.)@@ Российское кардиологическое научное общество. Российское научное медицинское общество терапевтов. Клинические рекомендации. Артериальная гипертензия у взрослых. 2020.Russian Scientific Medical Society of Therapists. Scientific Society of Gastroenterologists of Russia. Clinical recommendations. Non-alcoholic fatty liver disease in adults. 2022. (in Russ.)@@ Российское научное медицинское общество терапевтов. Научное общество гастроэнтерологов России. Клинические рекомендации. Неалкогольная жировая болезнь печени у взрослых. 2022.Russian Scientific Medical Society of Therapists. Scientific Society of Gastroenterologists of Russia. Clinical recommendations. Non-alcoholic fatty liver disease in adults. 2022. (in Russ.)@@ Российское научное медицинское общество терапевтов. Научное общество гастроэнтерологов России. Клинические рекомендации. Неалкогольная жировая болезнь печени у взрослых. 2022.Josloff K, Beiriger J, Khan A, et al.Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. J Cardiovasc Dev Dis. 2022;9(12):419. Published 2022 Nov 26. doi: 10.3390/jcdd9120419.Josloff K, Beiriger J, Khan A, et al.Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. J Cardiovasc Dev Dis. 2022;9(12):419. Published 2022 Nov 26. doi: 10.3390/jcdd9120419.Qiu YY, Zhang J, Zeng FY, Zhu YZ. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacol Res. 2023;192:106786. doi: 10.1016/j.phrs.2023.106786.Qiu YY, Zhang J, Zeng FY, Zhu YZ. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacol Res. 2023;192:106786. doi: 10.1016/j.phrs.2023.106786.Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. doi:10.1038/sigtrans.2017.23.Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. doi:10.1038/sigtrans.2017.23.Potoupni V, Georgiadou M, Chatzigriva E, et al. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol. 2021;36(11): 3002-3014. doi: 10.1111/jgh.15631.Potoupni V, Georgiadou M, Chatzigriva E, et al. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol. 2021;36(11): 3002-3014. doi: 10.1111/jgh.15631.Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143(5):1158-1172. doi: 10.1053/j.gastro.2012.09.008.Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143(5):1158-1172. doi: 10.1053/j.gastro.2012.09.008.Vachliotis ID, Polyzos SA. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Curr Obes Rep. 2023;12(3):191-206. doi: 10.1007/s13679-023-00519-y.Vachliotis ID, Polyzos SA. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Curr Obes Rep. 2023;12(3):191-206. doi: 10.1007/s13679-023-00519-y.Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, Chayama K. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis. 2012;44(6):492-496. doi: 10.1016/j.dld.2011.12.013.Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, Chayama K. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis. 2012;44(6):492-496. doi: 10.1016/j.dld.2011.12.013.Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol. 2004;287(4):R943-R949. doi: 10.1152/ajpregu.00265.2004.Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol. 2004;287(4):R943-R949. doi: 10.1152/ajpregu.00265.2004.Wei Y, Clark SE, Morris EM, et al. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol. 2008;49(3):417-428. doi: 10.1016/j.jhep.2008.03.018.Wei Y, Clark SE, Morris EM, et al. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol. 2008;49(3):417-428. doi: 10.1016/j.jhep.2008.03.018.Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012;302(6):H1219-H1230. doi: 10.1152/ajpheart.00796.2011.Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012;302(6):H1219-H1230. doi: 10.1152/ajpheart.00796.2011.Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.Zhang X, Wong GL, Yip TC, et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76(2):469-482. doi:10.1002/hep.32294.Zhang X, Wong GL, Yip TC, et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76(2):469-482. doi:10.1002/hep.32294.Siddiqui MT, Amin H, Garg R, et al. Medications in type-2 diabetics and their association with liver fibrosis. World J Gastroenterol. 2020;26(23):3249-3259. doi: 10.3748/wjg.v26.i23.3249.Siddiqui MT, Amin H, Garg R, et al. Medications in type-2 diabetics and their association with liver fibrosis. World J Gastroenterol. 2020;26(23):3249-3259. doi: 10.3748/wjg.v26.i23.3249.Pelusi S, Petta S, Rosso C, et al. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11(9):e0163069. Published 2016 Sep 20. doi: 10.1371/journal.pone.0163069.Pelusi S, Petta S, Rosso C, et al. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11(9):e0163069. Published 2016 Sep 20. doi: 10.1371/journal.pone.0163069.Borém LMA, Neto JFR, Brandi IV, Lelis DF, Santos SHS. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res. 2018;41(6):394-405. doi: 10.1038/s41440-018-0040-6.Borém LMA, Neto JFR, Brandi IV, Lelis DF, Santos SHS. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res. 2018;41(6):394-405. doi: 10.1038/s41440-018-0040-6.Efremova O.A., Chernobay P.E., Pogurelskaya E.P. Experience of using telmisartan, atorvastatin and ursodeoxycholic acid in patients with arterial hypertension in combination with non-alcoholic fatty liver disease. Сибирский научный медицинский журнал. 2021;41(5):75-82. (In Russ.) doi: 10.18699/SSMJ20210510. @@ Ефремова О.А., Чернобай П.Е., Погурельская Е.П. Опыт применения телмисартана, аторвастатина и урсодезоксихолевой кислоты у больных артериальной гипертонией в сочетании с неалкогольной жировой болезнью печени. Сибирский научный медицинский журнал. - 2021. - Т. 41, № 5. - С. 75-82. - doi: 10.18699/SSMJ20210510. - EDN HEWIUA.Efremova O.A., Chernobay P.E., Pogurelskaya E.P. Experience of using telmisartan, atorvastatin and ursodeoxycholic acid in patients with arterial hypertension in combination with non-alcoholic fatty liver disease. Сибирский научный медицинский журнал. 2021;41(5):75-82. (In Russ.) doi: 10.18699/SSMJ20210510. @@ Ефремова О.А., Чернобай П.Е., Погурельская Е.П. Опыт применения телмисартана, аторвастатина и урсодезоксихолевой кислоты у больных артериальной гипертонией в сочетании с неалкогольной жировой болезнью печени. Сибирский научный медицинский журнал. - 2021. - Т. 41, № 5. - С. 75-82. - doi: 10.18699/SSMJ20210510. - EDN HEWIUA.Musso G, Gambino R, Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol. 2010;21(1):76-83. doi: 10.1097/MOL.0b013e3283347ebb.Musso G, Gambino R, Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol. 2010;21(1):76-83. doi: 10.1097/MOL.0b013e3283347ebb.Huang X, Chen W, Yan C, et al. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. Biomed Pharmacother. 2019;118:109258. doi: 10.1016/j.biopha.2019.109258.Huang X, Chen W, Yan C, et al. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. Biomed Pharmacother. 2019;118:109258. doi: 10.1016/j.biopha.2019.109258.Adnan S, Nelson JW, Ajami NJ, et al. Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genomics. 2017;49(2):96-104. doi: 10.1152/physiolgenomics.00081.2016.Adnan S, Nelson JW, Ajami NJ, et al. Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genomics. 2017;49(2):96-104. doi: 10.1152/physiolgenomics.00081.2016.Li Y, Zhao D, Qian M, et al. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. Br J Pharmacol. 2022;179(9):2054-2077. doi: 10.1111/bph.15768.Li Y, Zhao D, Qian M, et al. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. Br J Pharmacol. 2022;179(9):2054-2077. doi: 10.1111/bph.15768.Xing SS, Tan HW, Bi XP, Zhong M, Zhang Y, Zhang W. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol Med. 2008;14(7-8):395-402. doi: 10.2119/2008-00024.Xing.Xing SS, Tan HW, Bi XP, Zhong M, Zhang Y, Zhang W. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol Med. 2008;14(7-8):395-402. doi: 10.2119/2008-00024.Xing.Mitten EK, Portincasa P, Baffy G. Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms. J Clin Transl Hepatol. 2023;11(5):1201-1211. doi: 10.14218/JCTH.2023.00029.Mitten EK, Portincasa P, Baffy G. Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms. J Clin Transl Hepatol. 2023;11(5):1201-1211. doi: 10.14218/JCTH.2023.00029.Kerbert AJ, Chiang FW, van der Werf M, et al. Hemodynamic response to primary prophylactic therapy with nonselective β-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(4):380-387. doi: 10.1097/MEG.0000000000000812.Kerbert AJ, Chiang FW, van der Werf M, et al. Hemodynamic response to primary prophylactic therapy with nonselective β-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(4):380-387. doi: 10.1097/MEG.0000000000000812.Gupta V, Rawat R, Shalimar, Saraya A. Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT. Hepatol Int. 2017;11(2):181-187. doi: 10.1007/s12072-016-9765-y.Gupta V, Rawat R, Shalimar, Saraya A. Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT. Hepatol Int. 2017;11(2):181-187. doi: 10.1007/s12072-016-9765-y.Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev. 2018;10(10):CD011510. doi: 10.1002/14651858.CD011510.pub2.Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev. 2018;10(10):CD011510. doi: 10.1002/14651858.CD011510.pub2.Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol. 2021;56(7):593-619. doi: 10.1007/s00535-021-01788-x.Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol. 2021;56(7):593-619. doi: 10.1007/s00535-021-01788-x.Russian Society for the Study of the Liver.Russian Gastroenterological Association. Clinical recommendations. Cirrhosis and fibrosis of the liver. 2021. (in Russ.)@@ Российское общество по изучению печени. Российская гастроэнтерологическая ассоциация. Клинические рекомендации. Цирроз и фиброз печени. 2021.Russian Society for the Study of the Liver.Russian Gastroenterological Association. Clinical recommendations. Cirrhosis and fibrosis of the liver. 2021. (in Russ.)@@ Российское общество по изучению печени. Российская гастроэнтерологическая ассоциация. Клинические рекомендации. Цирроз и фиброз печени. 2021.Okovity S.V., Raikhelson K.L., Volnukhin A.V., Kudlai D. A. Hepatoprotective properties of glycyrrhizic acid. Experimental and Clinical Gastroenterology. 2020;184(12): 96-108. (In Russ.) doi: 10.31146/1682-8658-ecg-184-12-96-108Okovity S.V., Raikhelson K.L., Volnukhin A.V., Kudlai D. A. Hepatoprotective properties of glycyrrhizic acid. Experimental and Clinical Gastroenterology. 2020;184(12): 96-108. (In Russ.) doi: 10.31146/1682-8658-ecg-184-12-96-108Mamedov M. N., Drapkina O. M. Choice of antihypertensive therapy in patients with arterial hypertension and chronic liver diseases. RFK. 2008. No. 4. (in Russ.)@@ Мамедов М. Н., Драпкина О. М. Выбор антигипертензивной терапии у больных с артериальной гипертонией и хроническими заболеваниями печени // РФК. 2008. №4.Mamedov M. N., Drapkina O. M. Choice of antihypertensive therapy in patients with arterial hypertension and chronic liver diseases. RFK. 2008. No. 4. (in Russ.)@@ Мамедов М. Н., Драпкина О. М. Выбор антигипертензивной терапии у больных с артериальной гипертонией и хроническими заболеваниями печени // РФК. 2008. №4.Lazebnik L.B., Komissarenko I.A., Mikheeva O.M. The choice of antihypertensive drug in a patient with arterial hypertension and liver pathology. Consilium Medicum. 2014; 16 (8): 24-27. (in Russ.)@@ Лазебник Л.Б., Комиссаренко И.А., Михеева О.М. Выбор антигипертензивного препарата у больного артериальной гипертонией и патологией печени. Consilium Medicum. 2014; 16 (8): 24-27.Lazebnik L.B., Komissarenko I.A., Mikheeva O.M. The choice of antihypertensive drug in a patient with arterial hypertension and liver pathology. Consilium Medicum. 2014; 16 (8): 24-27. (in Russ.)@@ Лазебник Л.Б., Комиссаренко И.А., Михеева О.М. Выбор антигипертензивного препарата у больного артериальной гипертонией и патологией печени. Consilium Medicum. 2014; 16 (8): 24-27.Ramandi A, George J, Merat S, et al. Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial. Hepatol Int. 2023;17(4): 882-888. doi: 10.1007/s12072-023-10542-9.Ramandi A, George J, Merat S, et al. Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial. Hepatol Int. 2023;17(4): 882-888. doi: 10.1007/s12072-023-10542-9.Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA) [published online ahead of print, 2023 Jun 21]. J Hypertens. 2023;10.1097/HJH.0000000000003480. doi: 10.1097/HJH.0000000000003480.Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA) [published online ahead of print, 2023 Jun 21]. J Hypertens. 2023;10.1097/HJH.0000000000003480. doi: 10.1097/HJH.0000000000003480.Hirata T, Tomita K, Kawai T, et al. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY) [published correction appears in Int J Endocrinol. 2014;2014:302602. Dosage error in published abstract; MEDLINE/PubMed abstract corrected].Int J Endocrinol. 2013;2013:587140. doi: 10.1155/2013/587140.Hirata T, Tomita K, Kawai T, et al. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY) [published correction appears in Int J Endocrinol. 2014;2014:302602. Dosage error in published abstract; MEDLINE/PubMed abstract corrected].Int J Endocrinol. 2013;2013:587140. doi: 10.1155/2013/587140.Baranova EI, Berezina AV, Melioranskaya EI, Polyakova EA. Safety and Efficacy of Amlodipine, Lisinopril and Rosuvastatin Therapy in Patients With Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Kardiologiia. 2015;55(10):68-75. doi: 10.18565/cardio.2015.10.68-75.Baranova EI, Berezina AV, Melioranskaya EI, Polyakova EA. Safety and Efficacy of Amlodipine, Lisinopril and Rosuvastatin Therapy in Patients With Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Kardiologiia. 2015;55(10):68-75. doi: 10.18565/cardio.2015.10.68-75.Leonova M.V., Yavelov I.S., Upnitsky A.A. et al edited by Leonova M.V. Clinical pharmacology in cardiology: a practical guide for doctors. Moscow: LLC Publishing House “Medical Information Agency”, 2023, pp. 78-98. @@ Леонова М.В., Явелов И.С., Упницкий А.А. и др. под ред. Леоновой М.В. Клиническая фармакология в кардиологии: практическое руководство для врачей. Москва: ООО «Издательство «Медицинское информационное агенство», 2023, стр. 78-98.Leonova M.V., Yavelov I.S., Upnitsky A.A. et al edited by Leonova M.V. Clinical pharmacology in cardiology: a practical guide for doctors. Moscow: LLC Publishing House “Medical Information Agency”, 2023, pp. 78-98. @@ Леонова М.В., Явелов И.С., Упницкий А.А. и др. под ред. Леоновой М.В. Клиническая фармакология в кардиологии: практическое руководство для врачей. Москва: ООО «Издательство «Медицинское информационное агенство», 2023, стр. 78-98.Leonova M.V., Yavelov I.S., Upnitsky A.A. et al. edited by Leonova M.V. Clinical pharmacology in cardiology: a practical guide for doctors. Moscow: LLC Publishing House “Medical Information Agency”, 2023, pp. 98-116. @@ Леонова М.В., Явелов И.С., Упницкий А.А. и др. под ред. Леоновой М.В. Клиническая фармакология в кардиологии: практическое руководство для врачей. Москва: ООО «Издательство «Медицинское информационное агенство», 2023, стр. 98-116.Leonova M.V., Yavelov I.S., Upnitsky A.A. et al. edited by Leonova M.V. Clinical pharmacology in cardiology: a practical guide for doctors. Moscow: LLC Publishing House “Medical Information Agency”, 2023, pp. 98-116. @@ Леонова М.В., Явелов И.С., Упницкий А.А. и др. под ред. Леоновой М.В. Клиническая фармакология в кардиологии: практическое руководство для врачей. Москва: ООО «Издательство «Медицинское информационное агенство», 2023, стр. 98-116.Farsang C, Dézsi CA, Brzozowska-Villatte R, De Champvallins M, Glezer M, Karpov Y. Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. Adv Ther. 2021;38(4):1776-1790. doi: 10.1007/s12325-021-01619-8.Farsang C, Dézsi CA, Brzozowska-Villatte R, De Champvallins M, Glezer M, Karpov Y. Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. Adv Ther. 2021;38(4):1776-1790. doi: 10.1007/s12325-021-01619-8.Zhou H, Toshiyoshi M, Zhao W, Zhao Y, Zhao Y. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine (Baltimore). 2023;102(26):e33981. doi: 10.1097/MD.0000000000033981.Zhou H, Toshiyoshi M, Zhao W, Zhao Y, Zhao Y. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine (Baltimore). 2023;102(26):e33981. doi: 10.1097/MD.0000000000033981.Duell PB, Welty FK, Miller M, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-e185. doi: 10.1161/ATV.0000000000000153.Duell PB, Welty FK, Miller M, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-e185. doi: 10.1161/ATV.0000000000000153.

The authors declare that there are no conflicts of interest present.